A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer

British Journal of Cancer

Volumn 98, Issue 1, 2008, Pages 22-24

  Shamash, J ^a   Davies, A ^a   Ansell, W ^a   McFaul, S ^a   Wilson, P ^a   Oliver, T ^a   Powles, T ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Endocrine sensitivity; Prostate cancer; Re induction

Indexed keywords

BICALUTAMIDE; CHLORAMBUCIL; CORTICOSTEROID; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ESTROGEN; ETOPOSIDE; GONADORELIN DERIVATIVE; LOMUSTINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; GLEASON SCORE; HORMONE SENSITIVITY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RETREATMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; DEXAMETHASONE; DIETHYLSTILBESTROL; ESTROGENS, NON-STEROIDAL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 38049039454     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604051     Document Type: Article

References (12)

1. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17(11): 3461-3467
2. Cavalli F, Beer M, Martz G, Jungi WF, Alberto P, Obrecht JP, Mermillod B, Brunner KW (1983) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J (Clin Res Ed) 286(6358): 5-8
3. Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT (2000) Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int 85(9): 1069-1073
4. Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93(22): 1687-1697. Review
5. Kalach JJ, Joly-Pharaboz MO, Chantepie J, Nicolas B, Descotes F, Mauduit C, Benahmed M, André J (2005) Divergent biological effects of estradiol and diethylstilbestrol in the prostate cancer cell line MOP. J Steroid Biochem Mol Biol 96(2): 119-129
6. Kim R, Tanabe K, Emi M, Uchida Y, Osaki A, Toge T (2005) Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Int J Oncol 26(4): 1025-1031
7. Nishimura K, Nonomura N, Yasunaga Y (2000) Low doses of oral dexamethasone for hormone refractory prostate carcinoma. Cancer 2570-2576
8. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [see comment]. N Engl J Med 351(15): 1513-1520
9. Shamash J, Barlow C, Wilson P, Ansell W, Oliver RTD (2005) Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity, an unexpected finding. Br J Cancer 92(1): 36-40
10. Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A (2006) Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res; 9(15):5550-8
11. 12(1): 169-174
12. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [see comment]. N Engl J Med 351(15): 1502-1512